Sparsentan

DRUG9 trials

Sponsors

Travere Therapeutics, Inc., University of Leicester, University of Edinburgh, Brigham and Women's Hospital, Waid City Hospital, Zurich

Conditions

ANCA Associated VasculitisAlport SyndromeAutoimmune DiseasesCardiovascular DiseasesFocal Segmental GlomerulosclerosisGlomerulonephritisGlomerulonephritis, IGAIgA Nephropathy (IgAN)

Phase 1

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

RecruitingNCT07224776

Brigham and Women's HospitalProteinuria, Proteinuria in Nephrotic Range, Proteinuric Kidney Disease +1

Start: 2026-07-10End: 2028-12-01Target: 20Updated: 2026-07-30

Phase 2

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

RecruitingNCT04663204

University of LeicesterAutoimmune Diseases, Glomerulonephritis, Glomerulonephritis, IGA +3

Start: 2020-12-10End: 2027-12-31Target: 24Updated: 2026-06-03

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

RecruitingNCT05003986

Travere Therapeutics, Inc.Alport Syndrome, Focal Segmental Glomerulosclerosis, IgA Vasculitis +2

Start: 2021-08-12End: 2027-04-12Target: 67Updated: 2026-05-12

ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

Active, not recruitingNCT05630612

University of EdinburghANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases

Start: 2022-12-08End: 2027-09-01Updated: 2026-08-26

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

CompletedNCT05856760

Travere Therapeutics, Inc.Immunoglobulin A Nephropathy

Start: 2023-05-19End: 2024-10-25Updated: 2025-11-20

Phase 3

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

CompletedNCT03493685

Travere Therapeutics, Inc.Focal Segmental Glomerulosclerosis

Start: 2018-04-17End: 2026-03-19Updated: 2026-04-17

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Active, not recruitingNCT03762850

Travere Therapeutics, Inc.Immunoglobulin A Nephropathy

Start: 2018-12-11End: 2026-07-01Updated: 2026-04-20

Phase 4

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Active, not recruitingNCT07219121

Travere Therapeutics, Inc.Focal Segmental Glomerulosclerosis, Immunoglobulin A (IgA) Nephropathy, Kidney Transplant +1

Start: 2025-10-07End: 2027-05-01Target: 20Updated: 2026-06-23

Unknown Phase

Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

Not yet recruitingNCT07555301

Waid City Hospital, ZurichIgA Nephropathy (IgAN)

Start: 2026-06-01End: 2029-12-31Target: 50Updated: 2026-04-29

Related Papers

Sparsentan - SGLT2 inhibitor combination therapy in trials of IgA nephropathy.

2026-09-11

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

Clinical Journal of the American Society of Nephrology2025-12-23

Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.

2025-12-22

Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan.

2025-11-20

#2444 Patients with focal segmental glomerulosclerosis (FSGS) achieved low proteinuria targets earlier and more often with sparsentan (SPAR) vs irbesartan (IRB) in DUPLEX

Nephrology Dialysis Transplantation2025-10-01

#1346 Population modelling depicts the mutational burden of NPHS2 (podocin) nephropathy and reveals an undiagnosed later onset genetic cohort

Nephrology Dialysis Transplantation2025-10-01

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

2025-06-101 citations

Ovid Embase search string.

OPAL (Open@LaTrobe) (La Trobe University)2025-06-10

PubMed search string.

OPAL (Open@LaTrobe) (La Trobe University)2025-06-10

Risk of bias assessment for all included RCTs.

OPAL (Open@LaTrobe) (La Trobe University)2025-06-10

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.

2024-01-281 citations

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.

2023-11-03157 citations

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

New England Journal of Medicine2023-11-0390 citations

Sparsentan and the Expanding Landscape of IgA Nephropathy Treatment

Clinical Journal of the American Society of Nephrology2023-07-272 citations

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.

2023-04-01150 citations

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.

2023-03-0420 citations

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.

2023-02-0940 citations

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Nephrology Dialysis Transplantation2020-08-10180 citations

Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease

Hypertension2019-06-1021 citations